Neuroendocrine Tumours – Pipeline Review, 2019

Neuroendocrine tumours basically occur in the neuroendocrine cells which possess properties of both, nerve cells and hormone-producing cells. Depending upon the tumour location, neuroendocrine tumours are classified as gastrointestinal neuroendocrine tumours, lung neuroendocrine tumours, pancreatic neuroendocrine tumours, and Zollinger-Ellison syndrome (small intestine). Discomfort or pain in the abdomen or rectum, diarrhoea, bleeding from the rectum or blood in the stool, and blockage in the intestine (bowel obstruction) are some of the commonly observed symptoms of gastrointestinal neuroendocrine tumours. According to National Institutes of Health, neuroendocrine tumours account for an estimated 0.5% all newly diagnosed cases of malignancies. 

Certain therapies such as somatostatin analogues, targeted therapy, radiofrequency ablation, and peptide receptor radionuclide therapy (PRRT) are commonly recommended in order to treat neuroendocrine tumours.

Pharmaceutical companies are prominently focusing on studying and developing new treatment options for the neuroendocrine tumours. For instance; Surufatinib, which is being studied by Hutchison Medipharma Limited, is currently in phase-3 clinical trials to check its efficacy and tolerability for the treatment of advanced extrapancreatic neuroendocrine tumors.

To know how our report can help streamline your business, Speak to Analyst

At present around 90% of the pipeline candidates for neuroendocrine tumours are in the phase-1 and phase-2 stage. Majority of the studies have been sponsored by pharmaceutical companies.

Report Description

The report on ‘Neuroendocrine Tumours – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Neuroendocrine Tumours. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Neuroendocrine Tumours.

The report on ‘Neuroendocrine Tumours – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players 

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Neuroendocrine Tumours
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Neuroendocrine Tumours
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary